Ideaya Biosciences (IDYA) announced a research collaboration with Attmos as part of its efforts to build a physics-based computational small molecule discovery platform that unlocks what are currently perceived as undruggable oncology targets. The collaboration will integrate Ideaya’s differentiated and proven capabilities in structural biology and pharmaceutical drug discovery across multiple oncology targets with Attmos’ capabilities in computational chemistry method development, high performance computing, and software development. The focus of the partnership will be to engineer and optimize a workflow solution for high-throughput absolute binding free energy perturbation predictions of drug candidate molecules.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Cautious Hold Rating on IDEAYA Biosciences Amid Anticipated Equity Raises and Financial Pressures
- IDEAYA Biosciences Reports 2024 Financials and Business Update
- IDEAYA Biosciences: Strategic Advancements and Promising Clinical Developments Support Buy Rating
- Strategic Advancements and Clinical Progress Drive IDEAYA Biosciences’ Buy Rating
- Ideaya Biosciences price target lowered to $40 from $53 at Oppenheimer